Hematology
Refine Search
Pharmaceutical
Swiss pharma giant Novartis will spotlight key data across its oncology portfolio, including Kisqali (ribociclib), Scemblix (asciminib) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which was recently approved for use prior to chemotherapy, at the upcoming 2025 ASCO Annual Meeting. 15 May 2025
Biotechnology
Privately-held Remedy Plan Therapeutics, a US pharma company developing novel, hyperbolic NAMPT inhibitors, has raised more than $18 million in an oversubscribed insider financing round. 13 May 2025
Biotechnology
Genmab posted a 19% rise in revenue to $715 million for the first quarter of 2025, driven by higher royalties and increasing sales of its lymphoma therapy Epkinly (epcoritamab). Earnings before interest and taxes rose to $188 million, up from $116 million a year earlier. 9 May 2025
Pharmaceutical
US pharma major Bristol Myers Squibb is planning a massive $40 billion investment in the country over the next five years. 7 May 2025
Biotechnology
Sino American biotech BeiGene, a global oncology company that will change its name to BeOne Medicines, today announced financial results and corporate updates from the first quarter 2025. 7 May 2025
Biotechnology
Priothera today announced the appointment of Jens Hasskarl, as its chief medical officer (CMO). 6 May 2025
Biotechnology
Sweden’s Mendus, a clinical-stage drug developer, has announced the appointment of Dr Tariq Mughal as chief medical officer, effective today, May 5. 5 May 2025
Pharmaceutical
UK drugmaker GSK ended Tuesday’s trading more than 2% higher after announcing its first-quarter financial results. 1 May 2025
Biotechnology
Regeneron Pharmaceuticals today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple myeloma. 28 April 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) late Friday announced it has granted a conditional marketing authorization for the Aucatzyl (obecabtagene autoleucel), a chimeric antigen receptor (CAR) T-cell therapy, to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 28 April 2025
Biotechnology
Chinese biotech LTZ Therapeutics has closed an oversubscribed series A+ financing round, raising $40 million to support its push into early-stage clinical development. 25 April 2025
Pharmaceutical
Swiss pharma giant Roche today reported that it achieved sales growth of 6% (7% in francs) to 15.4 billion francs ($18.8 billion) for the first three months of 2025. That topped projections for $18.34 billion, according to FactSet. 24 April 2025
Pharmaceutical
Bristol Myers Squibb beat Wall Street expectations in the first quarter of 2025, sending shares higher in early trading Thursday, as the company raised its full-year forecast on the back of favorable foreign exchange and solid performance from its newer medicines. 24 April 2025
Pharmaceutical
French pharma major Sanofi delivered a set of first-quarter financial results that seemed to satisfy markets Thursday, as its share price remained unchanged near close. 24 April 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi (marstacimab) to prevent or reduce bleeding in patients 12 years of age and older weighing at least 35kg with hemophilia A and B. 22 April 2025
Pharmaceutical
UK pharm major GSK has breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in the pharmaceutical industry, the trade group’s Prescription Medicines Code of Practice Authority (PMCPA) has revealed. 16 April 2025
Biotechnology
Johnson & Johnson has announced new data from an analysis modelling long-term progression free survival (PFS) in transplant eligible (TE) and transplant ineligible (TIE) newly diagnosed multiple myeloma (NDMM) patients given Darzalex (daratumumab)-subcutaneous (SC) therapy alongside bortezomib, lenalidomide and dexamethasone (VRd). 11 April 2025
Biotechnology
Solu Therapeutics, a US biotech developing therapies to eliminate disease-driving cells in cancer, immunology and other therapeutic areas, has announced the successful completion of a $41 million Series A financing. 10 April 2025
Biosimilars
Israel-based Teva Pharmaceuticals industries today revealed two important updates reflecting its commitment to expanding access to both biosimilars and innovative medicines. 7 April 2025
Biotechnology
The European Commission (EC) has approved an indication extension of Darzalex (daratumumab) subcutaneous (SC) formulation in the frontline setting. 7 April 2025
Biotechnology
New data from Johnson & Johnson's Phase III CARTITUDE-4 study highlight the performance of Carvykti (ciltacabtagene autoleucel) in multiple myeloma. 10 December 2024
Biotechnology
Johnson & Johnson has announced data highlighting that Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) negativity rates and progression-free survival (PFS) in newly diagnosed multiple myeloma (NDMM), regardless of transplant status. 9 December 2024
Biotechnology
Pierre Fabre has presented updated Phase III results for its investigational therapy tabelecleucel at the American Society of Hematology (ASH) Annual Meeting. 9 December 2024
Biotechnology
Dizal has announced the latest data from a pooled safety and efficacy analysis of DZD8586, a non-covalent blood-brain barrier (BBB) penetrant LYN/BTK dual inhibitor, in B-cell non-Hodgkin lymphoma (B-NHL). 9 December 2024
Biotechnology
AbbVie has announced updated results from the Phase Ib/II EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide and rituximab (R2) in relapsed or refractory (R/R) follicular lymphoma (FL). 9 December 2024
Biotechnology
Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to venetoclax led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukaemia (CLL). 9 December 2024
Pharmaceutical
Chinese biotech Abbisko Therapeutics has shared Phase II trial results for its oral CSF-1R inhibitor pimicotinib at the 66th ASH annual conference in San Diego. 9 December 2024
Biotechnology
Johnson & Johnson has unveiled positive early data for its multiple myeloma treatment Tecvayli (teclistamab) from two clinical studies focused on people with newly diagnosed multiple myeloma. 9 December 2024
Pharmaceutical
Sanofi has unveiled promising Phase III results for rilzabrutinib, its oral Bruton’s tyrosine kinase (BTK) inhibitor, at this year’s American Society of Hematology (ASH) meeting. 9 December 2024
Biotechnology
US biotech Regeneron Pharmaceuticals on Sunday announced positive updated Phase III data of an exploratory cohort from the ACCESS-1 trial investigating its first-in-class pozelimab and cemdisiran (poze-cemdi) combination treatment against ravulizumab, a standard-of-care complement factor 5 (C5) inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH). 9 December 2024
Pharmaceutical
Novartis today announced positive top-line results from APPULSE-PNH, a Phase IIIb study on the efficacy and safety of twice-daily oral monotherapy Fabhalta(iptacopan). 6 December 2024
Pharmaceutical
Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. 3 December 2024
Biotechnology
Nearly seven years after its founding, Senti Biosciences has announced promising results from its Phase I trial for SENTI-202. 3 December 2024
Pharmaceutical
The world’s hematologists are packing their bags in preparation for a visit to San Diego, California, for the American Society of Hematology (ASH) Annual Meeting and Exposition. Which companies’ data will they be looking out for? And which might take them by surprise? Our guide below offers a preview of some of the major presentations coming up. 1 December 2024
Pharmaceutical
A new indication for olverembatinib, developed by Suzhou-based Ascentage Pharma will be added to China’s National Reimbursement Drug List (NRDL) from next year. 28 November 2024
Pharmaceutical
The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield Capital Partners (UK) regarding a potential acquisition of Grifols shares. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze